Diadema Partners’s Entera Bio ENTX Stock Holding History

Diadema Partners’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.2K	Hold	23,260	–	–	0.01%	139
2026 Q1	$25.8K	Buy	+23,260	New	+$32.6K	﹤0.01%	136

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $606M AUM

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Diadema Partners's ENTX Position: Q2 2026 in Review

Diadema Partners held its Entera Bio (ENTX) position steady in Q2 2026 at 23,260 shares worth $41.2K. The position accounts for 0.01% of the portfolio, ranked #139.

Diadema Partners first reported a position in ENTX in Q1 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold ENTX as of Q2 2026.

Diadema Partners held 23,260 shares of Entera Bio worth $41.2K as of Q2 2026.
Diadema Partners left its Entera Bio share count unchanged in Q2 2026.
Entera Bio made up 0.01% of Diadema Partners's portfolio in Q2 2026, its #139 holding.
Diadema Partners first reported a position in Entera Bio in Q1 2026 and has held it in 2 quarters since.
27 funds tracked by Wall St. Rank held Entera Bio as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.